HAEMATOPOIETIC STEM ELL TRANSPLANTATION (HSCT) A process in which abnormal, malignant, or non- functioning marrow cells are replaced with normal marrow.

Slides:



Advertisements
Similar presentations
Hematopoietic Stem Cell Transplantation Lynn Savoie September 30, 2006.
Advertisements

Cancer 101 Monica Schlatter, RN, ND, AOCNP. Types of Cancer AIDS- related malignancies AIDS- related malignancies Bone and soft tissue sarcoma Bone and.
A Project on Bone marrow HASEEB TANVEER/ FOZIA TANVEER
Bone Marrow Transplant in Oncology
Blood and Marrow Transplant: The basics…what you need to know Resident Education Lecture Series.
Hematopoietic stem cell transplantation
BLOOD TRANSFUSION SUPPORT IN STEM CELL TRANSPLANT
Bone Marrow Transplant in Oncology. Source Pathology  Treat Leukemia by chemotherapy  Regeneration of normal marrow  Chemotherapy alone cannot eliminate.
Hematopoietic Stem Cells A hematopoietic stem cell is a cell isolated from the blood or bone marrow that can renew itself, can differentiate to a variety.
Blood and marrow stem cell transplantation A.Basi ADULT HEMATOLOGIST,ONCOLOGIST IRAN UNIVERSITY OF MEDICAL SCIENCES.
HAEMATOLOGY MODULE: LEUKAEMIA (LECTURE 1) CHEMOTHERAPY Adult Medical-Surgical Nursing.
Module 1 Haematopoietic stem cell transplantation.
Bone Marrow Transplantation. Unlike solid organ transplant, in bone marrow transplantation (BMT) the immunology goes two ways. There is host vs. ​ graft.
CHIMERISM & DLI Dr. Serdar ŞIVGIN Kayseri Feb, 2011.
Transplantation Autologous Syngeneic Allogeneic Xenogeneic.
Jeffrey Schriber, M.D. FRCP (c) Medical Director Cancer Transplant Institute Virginia G. Piper Cancer Center Everything You Ever Wanted to Know About Transplant.
Stem cells Stem cells are ‘generic’ cells that develop into particular types of cells. So they may become nerve cells, muscle cells, blood cells… in fact,
Transplantation Rejection of foreign tissue grafts is due to immune responses to alloantigens on the graft Blood group antigens Polymorphic MHC antigens.
Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2010 CIBMTR Summary Slides SUM10_1.ppt.
Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2011 Summary Slides Worldwide SUM-WW11_1.ppt.
Hematopoietic Stem Cell Transplant
Building Canada’s National Public Cord Blood Bank.
Engineered Cells and Tissues Locksley McGann, PhD Professor Department of Laboratory Medicine and Pathology University of Alberta 24 April, 2012 Analytics,
Introduction to Haematopoietic Stem Cell Transplantation (HSCT) Covenant Health System HSCT Program Lubbock, Texas April 4, 2007.
Stem cells are relatively ‘unspecialized’ cells that have the unique potential to develop into ‘specialized’ cell types in the body (for example, blood.
Basics of Stem Cell Transplant Tamila Kindwall-Keller, D.O. August 18, 2008.
Presented by: SELFIE. The demand for body parts and organ transplant exceeds the number of available donors. According to Biotechnology Industry Organization.
DR. YETUNDE T. ISRAEL-AINA PAEDIATRICIAN, UNIVERSITY OF BENIN TEACHING HOSPITAL, BENIN CITY BENIN BLOOD AND MARROW TRANSPLANT WORKSHOP, UNIVERSITY OF BENIN.
©2009 Carolina Biological Supply CompanySome images ©2009 Jupiterimages Corporation.
Hematopoietic stem cell transplantation- HSCT. Principle of HSCT Myeloablation and eradication of residual disease with hogh dose conditioning regimen.
DONOR LYMPHOCYTE INFUS I ON (DLI) Dr. Serdar ŞIVGIN February 2011 Kayseri.
STEM CELLS – ETHICAL ISSUES National 4 & 5 Biology – multicellular organisms.
Stem Cells By Sugandha Srivastav.
Bone marrow Transplant in Paediatric Haematology
Immunotherapy (Cancer therapy with T-Cells)
Chronic myeloid leukaemia Cancer of granulocyte production Too many (non functioning) granulocytes are produced Bone marrow is overcrowded with ineffective.
TRANSPLANTATION & tissue rejection
HAEMATOPOIETIC STEM ELL TRANSPLANTATION (HSCT) A process in which abnormal, malignant, or non- functioning marrow cells are replaced with normal marrow.
Autoimmune Diseases How Do the Immune Cells of the Body Know What to Attack and What Not To Attack ?
White blood cells and their disorders Dr K Hampton Haematologist Royal Hallamshire Hospital.
Blood Types A B AB O. Four major types of blood. A, B, AB, and O. Inherited from parents. Determined by presence or absence of an ANTIGEN on the surface.
Due to the non-myeloablative nature of the reduced intensity conditioning, following infusion there is a period of mixed-chimerism with both patient and.
Daunorubicin VS Mitoxantrone VS Idarubicin As Induction and Consolidation Chemotherapy for Adults with Acute Myeloid Leukemia : The EORTC and GIMEMA Groups.
HAPLOIDENTICAL STEM CELL TRANSPLANT
Hematopoietic Stem Cell Current Status and Future Directions
Hematopoietic Stem Cell Transplantation (HSCT)
Hematopoietic Stem-Cell Transplantation Edward A. Copelan, M.D. N Engl J Med 2006; 354: Review Article MEDICAL PROGRESS.
Bone Marrow Transplant
Ch 8.4 Stem Cell Basics - Ted Talk 4 mins
Blood and Marrow Transplant: The basics…what you need to know
Stem Cell Transplantation
RIC UCBT Transplantation of Umbilical Cord Blood from Unrelated Donors in Patients with Haematological Diseases using a Reduced Intensity Conditioning.
GVHD-Like Colitis in Renal Graft Recipient
Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2010 CIBMTR Summary Slides INTRODUCTION: The Summary Slides are an annual report.
Supplemental table 1 Patients' characteristics Variables Number
Man & Environment: Biomedical Development
Human Health and Disease
Stem Trend By:Katelin & Haley
Active management of veno-occlusive disease (VOD)
Transplantation Immunology
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION for MULTIPLE MYELOMA
Transplantation Rejection of foreign tissue grafts is due to immune responses to alloantigens on the graft Blood group antigens Polymorphic MHC antigens.
Cord blood transplantation and stem cell regenerative potential
Table 1.1.1: Stock and Flow of Blood and Marrow Transplantation,
Stem cells Stem cells are ‘generic’ cells that develop into particular types of cells. So they may become nerve cells, muscle cells, blood cells… in fact,
Transplantation Immunology
Biological Medicine By Benji Marks.
Introduction. Title: Activities and Outcomes of Hematopoietic Cell Transplantation in Japan.
Hematopoietic Stem Cell Transplantation Dr . Ghassemi A Associate professor of pediatric Hematologist Oncologist & stem cell transplantation.
HSCT in children with sickle cell Disease
Presentation transcript:

HAEMATOPOIETIC STEM ELL TRANSPLANTATION (HSCT) A process in which abnormal, malignant, or non- functioning marrow cells are replaced with normal marrow stem cells.

Two Kinds of Stem Cells Embryonic (also called “pluripotent”) stem cells are capable of developing into all the cell types of the body. Embryonic (also called “pluripotent”) stem cells are capable of developing into all the cell types of the body. Adult stem cells are less versatile and more difficult to identify, isolate, and purify. Adult stem cells are less versatile and more difficult to identify, isolate, and purify.

Source of Stem cells Stem cells may be derived from autologus, allogeneic or xenogenic sources. Histocompatability is prerequisite for transplantation of allogeneic stem cells. Fetal tissue is the best current tissue source for human neural stem cells, however ethical issues are a major concern.

Sources of haemopoetic stem cells  Bone marrow.  Peripheral blood stem cells(PBSC).  Placental (cord blood) blood transplant.  Fetal liver.

Placenta a Source of Stem Cells Placental stem cells, like umbilical cord blood and bone marrow stem cells, can be used to cure chronic blood- related disorders such as sickle cell disease, thalasemia, and leukaemia.

Umbilical Cord Blood Stem Cell Transplant Umbilical cord blood stem cell transplants are less prone to rejection than either bone marrow or peripheral blood stem cells. This is probably because the cells have not yet developed the features that can be recognized and attacked by the recipient's immune system

Normal BM cells are harvested from the donor& infusion into the pts after aggressive marrow ablative therapy. The success is compromised by the fact that the transplanted lymphocytes may treat with recipients tissues.

Allogeneic – Stem Cells-cont. Sources of stem cells from another donor (allogeneic) are primarily relatives (familial-allogeneic) or completely unrelated donors (unrelated-allogeneic). The stem cells in this situation are extracted from either the donor's body or cord blood

Autologus stem cell transplantation Is the process of harvesting, purging (treating for residual malignancy) and cryopreserving the patient's own marrow cells for re-infusion after high does chemotherapy or total body irradiation(TBI). Is the process of harvesting, purging (treating for residual malignancy) and cryopreserving the patient's own marrow cells for re-infusion after high does chemotherapy or total body irradiation(TBI).

Autologous Stem Cells – cont. Sources of the patient's own stem cells (autologous) are either the cells from patient's own body or his or her cord blood. For autologous transplants physicians now usually collect stem cells from the peripheral blood rather than the marrow. This procedure is easier, unlike a bone marrow harvest, it can take place outside of an operating room and the patient does not have to be under general anaesthesia. This procedure is easier, unlike a bone marrow harvest, it can take place outside of an operating room and the patient does not have to be under general anaesthesia.

AML (1st remission) ALL (high risk 1st CR, good risk 2nd CR) CMLCLLMDS Hodgkins disease NHL Multiple myeloma. 2-Defective haemopoiesis - Aplastic anaemia. - Sickle cell anaemia. - Thalassimia major. -Granulocyte disease. 3-Immunedeficiency 3-Immunedeficiency sever combined immune deficiency(SCID). sever combined immune deficiency(SCID). - Adenosine deaminase(ADA) deficiency - Adenosine deaminase(ADA) deficiency

20-50% of pts will experience one or more of the following : 1-Chemotherapy and radiation toxicity :   mucositis : GIT, respiratory tract, bladder.   Intrahepatic vascular occlusive disease (VOD).   Toxic pneumonitis.   CNS toxicity.   Endocrine dysfunction lead to hypothyoidisim.   Cataract.

2. Graft Versus host disease (GVHD) Acute days * Due to engrafment of donor T cell, that react against the recipient tissues. It can affect the skin,causing rashes, the liver, causing jaundice, and the gut, causing diarrhoea, and may vary from mild to lethal. Prevention includes HLA-matching of the donor, immunosuppressant drugs, including methotrexate, ciclosporin, alemtuzumab or antithymocyte globulin. Chromic 6-12 months It often resembles a connective tissue disorder (scleroderma- like), treated with corticosteroids and prolonged immunosuppression with, for example, ciclosporin.  Graft versus leukaemia effect?.

3. Infections : Due to immundeficiency & granulocytopenia : a-Bacterial infection G+ve, G.-ve. b-Fungal infection : candida albicans. c-Viral : Herpes zoster, CMV. d-Parasitic infection : Interstitial pneumonitis caused by Pneumocystis jiroveci Interstitial pneumonitis : -chemotherapy & radiation toxicity. -Mortality 50-90%.